Our team is excited to announce the $3.05B acquisition of our portfolio company, Halda Therapeutics, by Johnson & Johnson. Halda Therapeutics is a clinical-stage biotechnology company that has developed a proprietary RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) modality that works by a novel “hold and kill” mechanism for the precision treatment of cancer and other diseases. The novel mechanism of action of RIPTAC therapeutics is uniquely designed to address cancer’s ability to evolve bypass mechanisms of resistance, a common limitation of today’s precision oncology medicines. Congrats to Tim Shannon, Canaan GP & founding CEO of Halda Therapeutics, Craig Crews, repeat Canaan founder and Yale University Professor, and Chris Schade, current Halda Therapeutics CEO, Canaan EIR and repeat Canaan CEO, and the entire Halda Therapeutics Team! We’re grateful to our co-investors, advisors, clinicians, and especially the patients who made this progress possible. https://lnkd.in/emZB9nHQ
Canaan
Venture Capital and Private Equity Principals
San Francisco, California 22,166 followers
We’re an early-stage VC firm that invests in entrepreneurs with visionary ideas.
About us
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With a diversified fund and over 200 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 33+ years. Canaan’s focus areas include Consumer Tech, Enterprise, Fintech, Frontier Tech and Life Sciences. To learn more about our people and our portfolio, please visit canaan.com.
- Website
-
http://www.canaan.com
External link for Canaan
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- San Francisco, California
- Type
- Partnership
- Founded
- 1987
- Specialties
- Fintech, Enterprise SaaS, Digital Health, Biopharma Products & Platform, Medtech & Tools, Big Data /Cloud, Consumer, SaaS Security, and Frontier Tech
Locations
-
Primary
Get directions
27 South Park
Suite 201
San Francisco, California 94107, US
-
Get directions
2765 Sand Hill Road
Menlo Park, CA 94025, US
-
Get directions
285 Riverside Avenue
Suite 250
Westport, CT 06880, US
-
Get directions
821 Broadway, 3rd Floor
Public Entrance at 51 East 12th
New York, NY 10003, US
Employees at Canaan
Updates
-
Congratulations Dan Park and the Clutch team on welcoming Tom Flynn — former Vice Chair and CFO of BMO Capital Markets — to the Board. Exciting to see Clutch continue to build and scale with such an experienced team. https://lnkd.in/g7PuZrhY
Back in 2003, my first job out of school was at BMO Capital Markets. I joined the FIG group because of Tom Flynn's leadership and track record in the sector. My time working with Tom was incredibly formative early in my career. Since then, Tom went on to become CFO and Vice-Chair of BMO, and now, more than 20 years later, it’s come full circle. I’m thrilled to have the opportunity to work with Tom again – this time at Clutch. Welcome to the Board, Tom! Excited for what’s ahead. https://lnkd.in/gVbtHdSN Stephen Seibel Dillon Krasnigor Laura Chau Anshul Ruparell Richard Ball Andrew Black Alnoor Jiwani
-
Normunity, a Canaan company, is guiding the immune system’s T cells to more accurately find and attack tumor cells. Normunity has officially entered the clinic with its first cancer treatment, NRM-823 — a significant milestone for the team. NRM-823 is part of a new wave of cancer medicines. With this clinical trial now underway, Normunity is testing the therapy in patients with various types of solid tumors, building on the strong results from earlier laboratory studies. It’s a meaningful milestone that highlights the strength of Normunity’s drug discovery approach and the team behind it. #oncology #biotech #cancerresearch #immunotherapy @Tim Shannon https://lnkd.in/eGiJYbfW
-
Canaan company, Halda Therapeutics, shared positive first-in-human results for HLD-0915, a drug that has shown encouraging anti-tumor activity in patients with advanced, treatment-resistant prostate cancer. These findings are especially meaningful because the patients in the study had already undergone multiple prior treatments and had very few options left. While still early, this progress offers hope for patients, their families, and physicians. The results, presented at the #AACR-#NCI-#EORTC International Conference on Molecular Targets and Cancer Therapeutics, showed early signs that the oral therapy can slow tumor growth while being well-tolerated. Canaan’s Tim Shannon chairs Halda’s board, and we’re proud to support the company’s mission to advance innovative cancer therapies. https://lnkd.in/eEQdbTnn
-
Congratulations to the Sumble team! We’re proud to add Sumble to the Canaan portfolio and back founders Anthony Goldbloom and Ben Hamner as they build a breakthrough platform bringing context-driven AI to sales intelligence. Sumble is redefining how go-to-market teams discover and act on company and technology insights. Richard Boyle led our investment in Sumble. https://lnkd.in/gV4-BHvF
Sumble is building the data backbone of modern go-to-market (GTM) teams. Excited to announce that we’ve closed a $38.5M financing led by Canaan, Coatue Management, Square Peg with participation from Zetta Venture Partners, Bloomberg Beta and AIX Ventures as well as angels such as Marc Benioff and Nat Friedman. https://lnkd.in/gKET_2A8 We’re grateful to our early enterprise customers like Elastic, Snowflake, Wiz, Figma, Vercel, Weights & Biases, dbt Labs, Omni, Atlan and Dataiku for believing in us. We are hiring! We have open roles in design, full-stack and front-end engineering, machine learning, data science, and data engineering, growth and marketing: https://lnkd.in/gTwPg9yj
-
-
This weekend was a proud one for our team as we watched Vivace Therapeutics, Inc., a Canaan company that we have been working alongside since its inception, report an amazing data set for its lead program, VT3989, in treating #mesothelioma. The study results were featured in an oral presentation at the European Society for Medical Oncology (#ESMO) conference in Berlin and were concurrently published in Nature Medicine. Vivace's ongoing clinical trial of VT3989 demonstrated an overall response rate (ORR), a disease control rate (DCR), and progression-free survival (PFS) that far surpassed salvage chemotherapy benchmarks. Paired with an encouraging safety profile, these data support the advancement of VT3989 into a registrational Phase 3 study and suggest the potential for the drug to be the first new treatment approved for mesothelioma as its initial indication in more than 20 years. Vivace's story is one of ambition and impressive achievement. From setting out to develop a first-in-class drug against a completely novel #oncology target (#Hippo pathway) to working to bring a new therapy to patients with a notoriously difficult-to-treat #cancer type, the team has not shied away from the hardest of work that drug development has to offer. This past weekend represents a tremendous validation of the company's efforts to date, but there is still work to be done for patients with mesothelioma and their families. We look forward to continuing to stand with and support Vivace as it works to push VT3989 to the drug development finish line. Big shout out to Canaan’s own Tim Shannon, who is a founding member of the Vivace board. https://lnkd.in/ggivcV3N
-
Exciting news from our portfolio company Vivace Therapeutics, Inc. Therapeutics: Their experimental cancer drug VT3989 is showing real promise for mesothelioma patients who've already tried other treatments. In a recent study, nearly a third of patients saw their tumors shrink, and most patients saw their disease stabilize. These patients stayed progression-free for twice as long as with current standard treatments. The company plans to start a Phase 3 trial in early 2026—a critical step toward potential FDA approval. #Biotech #Oncology #Mesothelioma Tim Shannon https://lnkd.in/g4aPP9_9
-
Congratulations to the Arcade team on the addition of Varun Jampani as your Chief AI Officer! https://lnkd.in/gN8CARX8
We are excited to welcome Varun Jampani as our Chief AI Officer to help build the first AI creation and commerce platform at Arcade. Before joining Arcade, Varun was VP of Research at Stability AI, where he led the co-creation of Stable Diffusion 3.5. He previously held research roles at Google and NVIDIA, where he co-created DreamBooth and made foundational contributions to computer vision and generative AI. At Arcade, Varun will lead AI research and development to advance our platform’s ability to translate natural language into physical products. We’re thrilled to have Varun join us as we continue democratizing creation, unlocking human creative potential, and redefining what’s possible for individuals and communities everywhere. Press release: https://lnkd.in/gyqUWdnZ
-
-
Autonomous commerce is no longer science fiction—it's here. We're thrilled to have partnered with Motive Partners to bring together sharp operators from Stripe, Squarespace, and leading investors to discuss what this shift means for the industry.
The Future of Commerce is Here—And It Doesn't Need You to Click 🚀 Last week at Canaan, we co-hosted a mind-bending discussion with Motive Partners partners on agentic payments and the rise of autonomous commerce. The reality check? We're witnessing the most disruptive shift in payments since the credit card was invented. With Google's recent agentic protocol announcement (and others coming soon 👀), we brought together leaders from Stripe, Squarespace, transformation builders and visionary investors to tackle the big question: It's not IF autonomous transactions will dominate—it's WHO will capture the massive value being created. The infrastructure is already being built. The race is clearly on. Key takeaways for fintech & commerce builders, investors and leaders: ✅ Efficiency wins: Whether you call it "agentic commerce" or not, enabling seamless consumer and merchant experiences is everything; ✅ Performance is non-negotiable: Fast checkout, fraud management, optimized auth rates—these fundamentals still make or break you; ✅ Cross-platform dominance: Hyper-efficient buying and selling across every touchpoint will separate winners from casualties; ✅ Time horizon reality: Transforming shopping takes decades, not days—but the winners will capture exponential returns. Massive thanks to Dan Chandre, Sophie Sakellariadis, Mahmoud Arram, Brendan Dickinson for bringing their expertise and intellectual honesty to admit: we're all figuring this out together. And to Harsh Govil for moderating brilliantly and hosting us at your incredible venue. The future is autonomous. What are you building?
-
-
Doorstep is transforming last-mile delivery tracking and solving this $4B issue faced by delivery companies. Congratulations to the Doorstep team on their $8M seed investment! We're thrilled to lead this round and have Hrach Simonian join their board. https://lnkd.in/gNgTe9GN
Introducing Doorstep, the first indoor GPS for delivery platforms. It all started on my friend’s couch, when deliveries just wouldn't show up to the right door. I took a one-way ticket to New York and spent many nights sleeping in Antler’s office. Today, doorstep is live across every U.S. state, that’s more than 160M doors. For too long, delivery platforms have depended on unreliable proof-of-delivery photos. Support agents constantly lacked visibility. Chatbots give refunds with no context. Until now. Doorstep’s indoor tracking records exactly when and where a driver enters a building, which floor they reach, and the precise doorstep where the order is completed. It runs seamlessly in the background on the driver’s app. For delivery platforms, the impact is already clear: fewer disputes, faster resolutions, reduced fraud, shorter times to door, and billions saved through delivery efficiency. As a team, we’ve learned this one delivery at a time: building powerful sensor fusion algorithms that run without wifi, cell service, or additional hardware. Just pure physics and a few obsessed folks :) Today we’re announcing an $8M seed round led by Canaan, with participation from Antler, Cercano, CASSIUS, Kleiner Perkins scout Sean Henry and other key investors. Hrach Simonian, who also led Instacart’s seed, will be joining our board. Disputes, refunds, and failed deliveries shouldn’t be the cost of doing business. We are fixing that. DM me if you want to see it in action. Every delivery should end where it belongs: the Doorstep. Thank you Dominic-Madori Davis and TechCrunch for covering our journey so far. Pumped for what lies ahead!
-